News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
First Half 2008 Financial Results: NicOx SA Nears Completion of Phase 3 Naproxcinod Studies
July 28, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SOPHIA ANTIPOLIS, FRANCE--(Marketwire - July 28, 2008) - NicOx S.A. (Euronext Paris: COX) today reported its financial results for the six months ended June 30, 2008.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Earnings
Europe
MORE ON THIS TOPIC
Drug Development
Dren Bio lands $350M to push rare blood cancer therapy toward market
October 29, 2026
·
2 min read
·
Gabrielle Masson
Earnings
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
October 29, 2026
·
3 min read
·
Annalee Armstrong
Earnings
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
October 29, 2026
·
4 min read
·
Heather McKenzie
Earnings
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
October 29, 2026
·
4 min read
·
Gabrielle Masson
